#USA #Kessler Topaz #Radnor #FDA #uniQure N.V.

Investigation Notice for uniQure N.V. Investors

In the backdrop of significant stock declines, Kessler Topaz Meltzer & Check, LLP has announced an investigation into uniQure N.V. (NASDAQ: QURE). Following an unfortunate disclosure from the biopharmaceutical company on November 3, 2025, that the FDA found its data insufficient for supporting a crucial Biologics License Application (BLA) for AMT-130—its investigational gene therapy aimed at Huntington's disease—the company's stock witnessed a staggering drop of over 50%.

What Happened?

On October 31, 2025, the closing price of uniQure's stock stood at $67.69. However, just days later, news from the FDA prompted the price to plunge to $34.29 by November 3. uniQure revealed that the FDA had serious concerns regarding whether data from its Phase I/II trials could substantiate the BLA submission, which raised uncertainty about the timeline of the application process moving forward.

This development has understandably alarmed investors, and Kessler Topaz Meltzer & Check, LLP is urging those who have experienced significant losses due to this situation to reach out for assistance. The firm specializes in securities-fraud class actions and is committed to holding corporations accountable for potential violations.

Why Contact Kessler Topaz Meltzer & Check, LLP?

As a leading plaintiff-side law firm, Kessler Topaz has earned a reputation for its dedication to protecting the rights of investors. The firm has been recognized for its accomplishments in securities litigation, having represented both individual and institutional investors against large corporations when they face financial injustice.

The firm knows how to navigate the complexities of securities law, ensuring that investors are informed and armed with the legal recourse that might be available to them. If you are a uniQure investor and have suffered losses, reaching out can provide you with information on your options and possible next steps.

How to Get in Touch

Investors interested in learning more about the ongoing investigation or those wanting to file claims can do so by completing the online form available on the Kessler Topaz Meltzer & Check's website. Additionally, direct contact can be made with Jonathan Naji, Esq. at (484) 270-1453 or via email at [email protected].

For further information regarding this situation and the investigation process, visit Kessler Topaz Meltzer & Check.

Conclusion

The fallout from the FDA's feedback regarding uniQure's AMT-130 therapy has left many investors vulnerable. It is crucial for those affected to seek professional advice and understand their legal rights. Kessler Topaz Meltzer & Check, LLP stands ready to assist investors in navigating this troubling time to possibly recover their losses and ensure justice is served.